Shionogi Partners with Maze Therapeutics for MZE001’s Rights to Treat Pompe Disease
Shots:
- Following the completion of transaction and expiry of 30-day waiting period (as per US HSR Act), Shionogi and Maze Therapeutics have concluded an exclusive worldwide license agreement of MZE001, being developed for Pompe disease
- As per the agreement, Shionogi has obtained exclusive global rights of MZE001 along with related programs & IP by paying $150M up front and undisclosed development, regulatory & commercial milestones plus tiered royalties
- MZE001 is a GYS1 enzyme targeting small molecule, reducing muscle glycogen concentration. The P-I study suggests it as monotx. or as add-on therapy with enzyme replacement to treat Pompe disease
Ref: Shionogi | Image: Shionogi
Related News:- Shionogi Reports the P-III Trial Results for Ensitrelvir as a Treatment of Common COVID-19 Symptoms
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
